Over the course of the 20th century, the first generations of pioneering drug developers found success initially through chance discoveries in nature, then by mining small industrial chemical libraries, and finally by deliberately designing chemical compounds for specific targets. Drug developers began defining “ideal” drug properties –design criteria later formalized as Lipinski’s “Rule of 5” (Christopher A Lipinski, 1997), a framework originally established by a group of scientists at Pfizer to streamline development of small molecules. These properties were well suited for a narrow set of targets that were easy to reach with traditional pills and injections. However, as our understanding of human biology has expanded rapidly in recent years, so has the number of ways we can intervene. Recognizing the limitations of the old ways of thinking, today’s drug developers are deliberately stepping outside that box—creating new types of medicines that embrace the true complexity of disease, leaning into deeper biological understanding in order to tackle the biggest remaining unmet needs. More complex and sophisticated drugs are a defining feature of modern pipelines. These are not incremental improvements on older drug classes, but a significant shift that creates both enormous medical value and compelling investment opportunities in biotech Three powerful forces are pushing the industry in this direction.
1. We’re running out of low hanging fruit
From the 1980s through the early 2000s, small molecule drug discovery was built on “well-behaved” targets – proteins with clear structures and pockets for a chemical to bind and reliably change function. This paradigm was enormously productive, but it only covered a small fraction of the proteins in the human body: by most estimates, only 10–15% of human proteins are considered classically “druggable” by conventional small molecules, and many validated targets within that space have been heavily pursued. In many of these areas, successive waves of drugs have delivered incremental gains, with each new entrant outperforming the last and approaching the maximal clinical benefit for a given biological mechanism. In that context, spending hundreds of millions, or even billions, of dollars to develop yet another drug that can only hope to offer a small clinical advantage in a crowded, often genericized category is increasingly hard to justify.The targets that remain, even when strongly linked to disease, often break the old rules. For example, some targets don’t have traditional binding pockets or have functions independent of their binding pocket. Others have low or variable expression across patients or exist in hard-to-access tissues. The nature of these challenges is pushing drug design toward more sophisticated mechanisms or entirely new modalities.
The same pattern is repeating across the industry. While the low-hanging fruit era rewarded simpler molecules, accessing the large remaining opportunity set increasingly demands we explore the frontiers of what is possible with emerging drug technologies.
2. We can finally see disease in “high definition”
The techniques scientists use to study disease have improved dramatically. Recent additions to the toolbox include CRISPR-based screens, single-cell sequencing, which profiles gene activity in single cells rather than averaging across millions, and spatial transcriptomics, which maps that gene activity in tissue, showing exactly where those single cells sit relative to their neighbors. Modern biomedical researchers can track, cell by cell, how signaling pathways, cell states and different cell types interact in real patient tissue as disease progresses over time.These discovery tools reshaped drug development in two important ways:
- They improve how we evaluate potential drugs. More sophisticated experimental systems now let us test whether a drug is truly hitting the right biology in a meaningful way, early in the process. This helps distinguish a flawed hypothesis from a strong hypothesis with a flawed drug, saving the industry from investing years and tens or hundreds of millions of dollars that might otherwise be spent on candidates that never had a chance.
- They help match the right drug to the right patients. Chronic obstructive pulmonary disease (COPD) is a striking example. For years, every new therapeutic approach against COPD failed, in part because COPD was treated as a single disease. High-resolution tools revealed that COPD actually consists of at least two distinct inflammatory subtypes. That insight led to the first biologic therapy approved for one specific COPD subtype and is now guiding a pipeline of other targeted approaches.
This sharper picture of biology is also reshaping what drugs look like. In fibrosis, for example, single-cell RNA sequencing has identified distinct cell populations and signaling loops that offer drug targets with far more potential for precision than the “blunt” anti-fibrotic approaches that have historically struggled in the clinic. In oncology, spatial transcriptomics has revealed distinct immune niches within tumors. This discovery spurred the development of bispecific antibodies, which can bind two different targets at once to engage specific immune cells to attack cancer cells with much more precision than traditional antibodies. The throughline is clear: as higher-resolution tools expose the true granularity of disease, blunt therapeutic approaches give way to multi-specific, conditional, and context-dependent drugs engineered to intervene with corresponding precision.
3. Big, complex diseases are now in the crosshairs
A crucial overlay to this strategy is safety. A drug prescribed to millions of patients for chronic use operates under a fundamentally different risk tolerance than one reserved for rare or acutely life-threatening conditions. Side effects that might be acceptable in a small, high-risk group become disqualifying in a primary care setting. That higher bar forces developers to engineer far greater selectivity and precision into their drugs – which, in turn, adds even further complexity and development cost.
What this means for biotech and investors
The move toward more complex drugs is reshaping the entire biotech ecosystem.
- AI and other new tools are central to design. The number of design decisions behind a modern therapeutic—its sequence, 3‑D structure, manufacturability, stability, and on‑ and off‑target activity across multiple pathways—has grown beyond what traditional trial‑and‑error can handle. This creates a natural opening for AI‑native drug companies that can explore vast design spaces and optimize molecules in silico before they ever reach the lab, improving efficiency and timelines significantly in early development.
- The boundaries of medicinal chemistry itself are expanding, and so are development costs. The industry is increasingly venturing beyond the Rule of 5. These classic rules that once constrained small molecule design are being stretched as companies pursue new modalities that sit between conventional pills and large biologics. Developers are accepting the extra work required to fine-tune these molecules because the payoff can be highly differentiated products that competitors cannot easily copy, but complex molecules introduce their own cost pressures. All else equal, a more complex molecule requires more iterations to get right, and this holds across modalities. A bispecific antibody, for example, requires multiples more design-test cycles, as it must be optimized for each binding arm independently, and then re-optimized when the arms are combined. Novel modalities may also demand new production capabilities, where the cost of process design, optimization, scale-up, and even raw materials sourcing can be substantial and land early in development.
- Automation as a force multiplier. End-to-end automation can offset much of the added cost and complexity of modern drugs by cutting cycle times, reducing human error, and enabling smaller teams to run far more experiments and productions runs than previously possible. As these automated infrastructure layers mature, they become reusable assets, allowing the most forward-leaning companies to develop complex therapies faster, at lower marginal cost, and with a level of consistency that can translate into real competitive advantage.
- Trials and regulations are also becoming more complex. Novel modalities often require specialized administration and monitoring, longer or less predictable follow-up windows, new kinds of endpoints, and more sophisticated patient stratification to demonstrate efficacy in biologically heterogeneous populations. Regulatory pathways, too, have fragmented as agencies work to keep pace with novel modalities, creating a patchwork of guidance that sponsors must navigate.
Overall, these shifts raise the bar for capabilities and cost, but they also increase the potential upside for teams that get it right – whether through selecting the right targets based on a deep understanding of complex disease biology, matching up the right drug type for the target and patient population, or employing AI-driven design and optimization. Complexity, when harnessed thoughtfully, becomes a source of sustained advantage rather than just added cost.
A durable trend, not a passing phase
Taken together, these forces suggest that increasing drug complexity is not a temporary phase but a structural shift in how modern medicines are conceived, built, and brought to patients. The simple targets have largely been addressed. Our tools now reveal disease in far greater detail. The largest remaining opportunities are in common, heterogeneous conditions where patients and payors expect both strong efficacy and excellent safety.